Bristol-Myers Squibb has tightened rules on the way its sales representatives work with doctors in China after a $14m settlement over bribery allegations.
The US drugmaker said it had halted “certain initiatives” in China when asked to comment on reports of an overhaul in its sales practices in the second-largest pharmaceuticals market.
BMS agreed in October to settle charges by the US Securities and Exchange Commission that its majority-owned Chinese joint venture had reaped more than $11m in profits while violating the Foreign Corrupt Practices Act.
您已閱讀26%（555字），剩余74%（1612字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。